Table 3

Association between Lp-PLA2 activity and CAVS risk

Per 1 SD unit
Unadjusted1.33 (1.16 to 1.52)*
Model 11.35 (1.17 to 1.55)*
Model 21.22 (1.05 to 1.42)*
Model 31.21 (1.04 to 1.41)*
  • Data are presented as OR (95% CI).

  • Model 1 is adjusted for age and sex.

  • Model 2 is adjusted for age, sex, body mass index, diabetes, smoking and lipid-lowering therapy use.

  • Model 3 is adjusted for age, sex, body mass index, diabetes, smoking, lipid-lowering therapy use and creatinine levels.

  • *P<0.0001 (n=890).

  • CAVS, calcific aortic valve stenosis; Lp-PLA2, lipoprotein-associated phospholipase A2.